Disease Topics

Disease Topics

48 Disease areas packed with insight

Disease Topics

Knowledge Centres

Diagnosis, patient management, treatment strategies & decision support

Drug Database

Drug Database

Summary information on thousands of prescription drugs available in 9 languages

News

News

News written for doctors around pharmacological development

Treatment Guidelines

Clinical Guidelines

Professional association and governmental guidance on treatment

Disease Topics

Clinical Trials

Medical research & drug development - current and past landmark studies

Medical Journals

Medical Journals

Journal articles, titles and extracts from respected publishers

Disease Topics

Medical Apps

All the latest free and paid-for Apps selected for doctors

Welcome to epgonline.org - the website for healthcare professionals

What's new? The Bedwetting Knowledge Centre

Bedwetting, or nocturnal enuresis is defined as intermittent incontinence while sleeping. Applicable to children ≥ 5 years old, wetting episodes of any type that occur in discrete amounts are indicative to nocturnal enuresis.1,2

Due to variations in comorbidity, treatment response and pathogenesis, nocturnal enuresis can be divided into two subgroups – monosymptomatic nocturnal enuresis (MNE) and non-monosymptomatic nocturnal enuresis (NMNE).1,3 Absence of lower urinary tract symptoms or a history of bladder dysfunction is characteristic of MNE, while NMNE is defined as nocturnal enuresis accompanied by daytime urinary symptoms.

Nocturnal enuresis can have a profound impact on the child and their family, lowering a child’s self image, causing behavioural problems and affecting school performance. However, successful treatment improves the mental health of the child and brings practical relief to the family.

Latest News

UK will fund Sovaldi for patients with acute liver failure or those awaiting transplantation- Gilead

19-Apr-2014

The NHS England’s Clinical ...

FDA approves Arzerra combination therapy for CLL-GSK/Genmab

19-Apr-2014

The FDA has approved a Supplemental ...

FDA approves Ragwitek for treating Ragweed-induced Allergy - Merck

19-Apr-2014

The FDA has approved Ragwitek (Short ...

Topotarget and Bioalliance to merge

19-Apr-2014

BioAlliance Pharma SA a company ...

FDA approves Tanzeum for use in Type 2 Diabetes-Glaxo Smith Kline

17-Apr-2014

The FDA has approved Tanzeum ...

BAX 111 completes successful Phase III trial for von Willebrand Disease- Baxter

17-Apr-2014

Baxter International Inc. announced ...

FDA approves Grastek for grass pollen-induced Allergic Rhinitis- Merck Inc.,

16-Apr-2014

Merck announced that the FDA has ...

Recent Updates

Drugs

Clinical Guidelines

Antisocial behaviour and conduct disorders in children and young people: recognition, intervention and management

Guidelines for prevention and control of group A streptococcal infection in acute healthcare and maternity settings in the UK

Antithrombotics: indications and management

Guidelines on Reporting and Grading of Complications after Urologic Surgical Procedures

Medical Journals

Schizophrenia: A five-year follow-up of patient outcome following psycho-education for caregivers

Icotinib versus gefitinib in previously treated advanced non-small-cell lung cancer (ICOGEN): a randomised, double-blind phase 3 non-inferiority trial

Bandages or Double Stockings for the Initial Therapy of Venous Oedema? A Randomized, Controlled Pilot Study

Muscle paresis and passive stiffness: Key determinants in limiting function in Hereditary and Sporadic Spastic Paraparesis

epgonline.org Social